Inhalation delivery of topotecan is superior to intravenous exposure for suppressing lung cancer in a preclinical model
Intravenous (IV) topotecan is approved for the treatment of various malignancies including lung cancer but its clinical use is greatly undermined by severe hematopoietic toxicity. We hypothesized that inhalation delivery of topotecan would increase local exposure and efficacy against lung cancer whi...
Main Authors: | Philip J. Kuehl, Marcie J. Grimes, Devon Dubose, Michael Burke, David A. Revelli, Andrew P. Gigliotti, Steven A. Belinsky, Mathewos Tessema |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2018-01-01
|
Series: | Drug Delivery |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/10717544.2018.1469688 |
Similar Items
-
Inhalation delivery dramatically improves the efficacy of topotecan for the treatment of local and distant lung cancer
by: Philip J. Kuehl, et al.
Published: (2021-01-01) -
Therapeutic uses of topotecan for thoracic malignancies
by: Saoirse O. Dolly, et al.
Published: (2011-12-01) -
Impact of selected construction elements of capsule-based dry powder inhalers on the manner of drug delivery to the lungs
by: Marcin Odziomek, et al.
Published: (2016-12-01) -
Preclinical Evaluation of Oral Metronomic Topotecan and Pazopanib for the Treatment of Aggressive Extracranial Pediatric Solid Tumors
by: Kumar, Sushil
Published: (2013) -
Preclinical Evaluation of Oral Metronomic Topotecan and Pazopanib for the Treatment of Aggressive Extracranial Pediatric Solid Tumors
by: Kumar, Sushil
Published: (2013)